26 results
The primary aim of this trial is to determine the recommended safe dose and schedule of ModraDoc006/r in castration-resistant prostate cancer (CRPC) patients. The first 5 CRPC patients in this study showed a different pharmacokinetic profile, as…
Primary Objective• To evaluate the local safety and tolerability of INM-755 cream following repeated once-daily topical applications for 14 consecutive days on wounded skin of healthy volunteers. Secondary Objectives• To evaluate the systemic safety…
Primary: Time to first occurrence of MACE (cardiovascular death, myocardial infarction, or stroke) [Non-inferiority].Secondary: Time to first occurrence of MACE [Superiority], MACE or urgent revascularization for unstable angina, individual…
- evaluation of the safety of extended use of ModraDoc006/r - provide longterm access to ModraDoc006/r treatment for patients who have completed a phase I trial with ModraDoc006/r and who might have benefit from longterm treatment with weekly…
We will develop a bi-daily low-dose metronomic treatment schedule with paclitaxel in a convenient oral formulation and test whether this therapy has significant anti-angiogenic and anti-tumor activity.
To determine the maximum tolerated dose (MTD) of ModraDoc006/r (as ModraDoc006 10 mg tablets in combination with one tablet of 100 mg ritonavir) that can safely be administered in a bi-daily weekly schedule in combination with high-dose intensity…